GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Wanbury Ltd

Wanbury Ltd Receives ANVISA Approval for Metformin HCl API from Brazil FDA

REGULATORY ▲ Positive Development LOW RISK
📅 Filed on BSE: 12 Nov 2026, 11:27 AM IST  ·  BSE ID: e07fa1a8-7c06-4f1a-b70f-ce97a99dbc96
View Original BSE Filing (PDF)
💡
In Simple Terms
Wanbury got approval from Brazil's drug regulator for a key product, its third such approval from the agency.
🤖 AI Summary
  • Wanbury Ltd received ANVISA regulatory approval (Letter of suitability for API) for Metformin HCl EP grade.
  • This is the third consecutive API approval from ANVISA (Brazil FDA) for Wanbury Limited.
  • The approval enables customers to use Wanbury's APIs for pharmaceutical formulations.
  • Wanbury is initiating talks with customers to increase business volumes.
🏢 How This Affects the Company
📈
Business Impact
This ANVISA approval allows Wanbury to supply its Metformin HCl API to Brazilian pharmaceutical manufacturers, potentially expanding its customer base and market reach in Brazil. The company is actively seeking to increase business volumes with existing and new customers.
💰
Financial Impact
Securing regulatory approvals for key APIs can lead to increased sales and revenue. Further discussions with customers to increase volume will determine the extent of financial impact.
⚙️
Operational Impact
The approval validates Wanbury's API quality and compliance standards, supporting its export capabilities and international market penetration strategies.
⚠️
Risk Impact
This approval mitigates regulatory risk in Brazil and strengthens Wanbury's position in the API export market. No new risks are introduced by this filing.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this regulatory approval announcement.
👤
Who Is Affected
All shareholders are potentially affected by the expanded market access and business opportunities for Wanbury's API products in Brazil.
🔍
Management Signal
Management's focus on securing multiple international regulatory approvals signals a commitment to export growth and product quality excellence.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Customer discussions outcome on increased API volumes
Future ANVISA or other major regulatory body approvals
Subsequent financial results reporting export sales growth
LOW RISK Regulatory approval from a major agency reduces market entry barriers and validates product quality.
💡 Investor Takeaway
Wanbury Ltd secured its third ANVISA API approval for Metformin HCl EP grade, enabling Brazilian formulation use and prompting customer talks for increased business volume.
⚖️ Strengths & Concerns

✅ Positives

  • Third consecutive API approval from ANVISA (Brazil FDA) validates product quality and export compliance.
  • Regulatory clearance enables increased API supply for pharmaceutical formulations in Brazil, supporting business growth.
📅 Company Track Record
Wanbury Limited previously received regulatory clearance from Korea's MFDS with zero observations, highlighting its API export compliance.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What regulatory approval did Wanbury Ltd receive from ANVISA?
Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its Metformin HCl EP grade.
What is the significance of the ANVISA approval for Wanbury's Metformin HCl API?
This is Wanbury's third consecutive approval from ANVISA for its APIs, enabling customers to use its APIs for formulations and potentially increasing business volumes.
Which product received approval from ANVISA for Wanbury?
The approved product is Wanbury's flagship product, Metformin HCl EP grade.
What action is Wanbury Limited taking following the ANVISA approval?
Wanbury Limited has initiated talks with various customers to increase the volume of business from its customers.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.